Hematologic Malignancies: Multiple Myeloma

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.

The SWOG S0777 trial data shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

A triplet of elotuzumab, lenalidomide, and dexamethasone produced sustained improvements in both progression-free survival and overall survival in patients with relapsed/refractory multiple myeloma, according to a 3-year analysis of the phase III ELOQUENT-2 trial.

Adding the monoclonal antibody daratumumab to standard multiple myeloma regimens showcased responses in 81% of patients with relapsed or refractory myeloma that were

An oral treatment combination of ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival in comparison to lenalidomide and dexamethasone alone for relapsed/refractory multiple myeloma.

Gene therapy has potential to deliver lasting remissions in patients with advanced B-cell malignancies who have undergone allogeneic hematopoietic stem cell transplant, according to research presented by James N. Kochenderfer, MD.